Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.
AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce
Google teams up with PwC for DOD EHR project bid; FDA approves first weight-loss device since 2007; research says opioid abuse may be on the decline.
The fifth annual Xerox survey of patients and electronic health records shows patients have high expectations for the digital data.
As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.
A trio of doctors make a case for putting limits on digital promotions, including those in EHRs and through social networks.
Physicians Desk Reference is on a mission to expand its image beyond just being that heavy book doctors consult for information
CMS could provide more guidance for how to crack down on healthcare fraud, the OIG asserts in a report.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
EHRs could be a vehicle for pharma to find its way into the physician's workflow. First, industry needs to learn how to leverage them appropriately.
The state's first patient portal has officially entered development, and the e-health firm leading the effort said that a former WebMD executive joined its board.
The company is being purchased by medical cloud networker Athenahealth.
Monthly Prescribing Reference's first revamp in three years includes new features which have already attracted new users. VP of product development Tammy Chernin told MM&M these changes are just the beginning.
The med-ed company is buying Amazing Charts, a tie-up the firms say will enable them to deliver customized education to physicians and then assess the patient-level impact.
The DIA and the Healthcare Businesswomen's Association formalized a multi-year partnership, and GSK began shipping vaccine for the 2012-2013 flu season
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.